A Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men | Zendy

Herjan J.T. Coelingh Bennink | Zendy; Yvette Zimmerman | Zendy; Carole Verhoeven | Zendy; Alice E. Dutman | Zendy; Tjeert T. Mensinga | Zendy; Cornelis Kluft | Zendy; Yacov Reisman | Zendy; F.M.J. Debruyne | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Dose-Escalating Study With the Fetal Estrogen Estetrol in Healthy Men

Author(s) -

Herjan J.T. Coelingh Bennink,

Yvette Zimmerman,

Carole Verhoeven,

Alice E. Dutman,

Tjeert T. Mensinga,

Cornelis Kluft,

Yacov Reisman,

F.M.J. Debruyne

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-00147

Subject(s) - medicine , endocrinology , testosterone (patch) , estrogen , endocrine system , placebo , luteinizing hormone , pharmacodynamics , context (archaeology) , sex hormone binding globulin , prostate cancer , hormone , androgen , cancer , pharmacokinetics , paleontology , alternative medicine , pathology , biology

Luteinizing hormone-releasing hormone (LHRH) agonists have replaced estrogens for endocrine treatment of advanced prostate cancer (PC) because of cardiovascular side effects. The fetal estrogen estetrol (E4) may be safer for PC treatment and is expected to decrease testosterone (T) and prevent estrogen deficiency.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research